Zentalis Pharmaceuticals, Inc.
ZNTL
$4.18
$0.030.60%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 142.48% | -65.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.86% | 2.14% | |||
| Operating Income | -9.86% | -2.14% | |||
| Income Before Tax | -1.32% | -30.28% | |||
| Income Tax Expenses | -72.85% | -- | |||
| Earnings from Continuing Operations | -0.39% | -31.94% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -0.39% | -31.94% | |||
| EBIT | -9.86% | -2.14% | |||
| EBITDA | -9.92% | -2.16% | |||
| EPS Basic | -2.38% | -32.81% | |||
| Normalized Basic EPS | -5.31% | -28.72% | |||
| EPS Diluted | -2.38% | -32.81% | |||
| Normalized Diluted EPS | -5.31% | -28.72% | |||
| Average Basic Shares Outstanding | -1.95% | -0.66% | |||
| Average Diluted Shares Outstanding | -1.95% | -0.66% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||